查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2040904

磺胺類藥物市場預測至2034年—按類型、劑型、給藥途徑、應用、最終用戶和地區分類的全球分析

Sulphonamides Market Forecasts to 2034 - Global Analysis By Type (Sulfamethoxazole, Sulfadiazine, Sulfacetamide, Sulfasalazine, Sulfadoxine and Other Types), Formulation, Route of Administration, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球磺胺類藥物市場規模將達到 1.4153 億美元，並在預測期內以 7.1% 的複合年成長率成長，到 2034 年達到 2.45 億美元。

磺胺類藥物是一類常用的合成抗菌劑，用於治療細菌感染疾病。它們透過競爭性抑制細菌葉酸合成，抑制細菌必需的代謝過程，進而抑制細菌生長。全身性磺胺類藥物類藥物可經由口服或腸外途徑給藥，用於治療全身性感染疾病；而局部用藥則用於治療局部感染。磺胺類藥物用途廣泛，可用於人類和獸醫領域。

根據美國國家生物技術資訊中心（NCBI）統計，美國每年報告的蜂窩組織炎炎病例超過1400萬例，使其成為最常見的細菌性皮膚感染疾病之一。這導致每年65萬人住院治療，門診醫療費用約37億美元。

感染疾病增加

隨著全球感染疾病率的上升，對磺胺類藥物藥物的需求日益成長，這類藥物對治療細菌感染疾病非常有效。由於迫切治療方法各種細菌性疾病，製藥業預計此類藥物的使用量將會增加。在人口成長迅速且醫療基礎設施正在發展的地區，這一趨勢尤其明顯，進一步凸顯了磺胺類藥物藥物在應對感染疾病持續挑戰方面發揮的重要作用。

人們越來越擔心副作用

患者和醫護人員都對皮疹和過敏反應等潛在副作用表示擔憂，這阻礙了該藥物的廣泛應用。患者和醫護人員對潛在不利事件的擔憂影響了該藥物的整體普及。對副作用風險的擔憂可能導致患者用藥依從性降低，以及醫生在開立磺胺類藥物藥物時猶豫不決。這種擔憂可能導致人們傾向於選擇其他抗生素和治療方法，這可能會阻礙市場成長。

人口成長與醫療基礎建設發展

隨著人口成長，細菌感染疾病的發生率也隨之增加，導致對有效治療方法的需求日益成長。醫療設施的改善，尤其是在發展中地區，提高了磺胺類藥物的可近性並擴大了其使用範圍。醫療基礎設施的完善提高了診斷和治療水平，促進了磺胺類藥物在各種感染疾病治療中的應用。人口成長與醫療能力提升之間的這種動態協同作用，正使磺胺類藥物成為滿足快速發展社會日益成長的醫療需求的重要組成部分。

抗菌頻譜有限

在需要頻譜抗菌的情況下，醫生通常會優先選擇其他抗生素。為了進行全面治療，醫生可能會選擇作用範圍更廣的抗生素。由於磺胺類藥物的作用範圍有限，它們可能被排除在治療方案之外，導致其應用範圍和市場佔有率受限。這種限制限制了磺胺類藥物的通用性，並在需要廣譜頻譜才能有效治療性介入的情況下構成挑戰。

新冠疫情的感染疾病

新冠疫情擾亂了磺胺類藥物藥物市場造成了衝擊。醫療衛生工作的重點轉移到應對疫情上，常規治療受到影響。除了生產和分銷管道中斷外，經濟的不確定性也進一步影響了磺胺類藥物市場。然而，鑑於某些磺胺類藥物在治療細菌感染疾病的重要性，市場需求似乎得以維持，並且在全球醫療保健格局的大背景下，市場正在積極適應持續的挑戰。

在預測期內，平板電腦細分市場預計將成為最大的細分市場。

片劑市場預計將呈現強勁成長。磺胺類藥物藥物片劑是一種抗菌劑，在治療細菌感染疾病發揮至關重要的作用。這些片劑含有磺胺類化合物，可透過抑制葉酸合成來抑制細菌生長。磺胺類藥物藥物片劑常用於治療尿道感染、呼吸道感染疾病和其他細菌性疾病，提供了一種標靶治療方案。目前的研究旨在改進製劑並克服挑戰，以確保磺胺類藥物藥物片劑持續保持療效，並在應對各種細菌感染疾病發揮重要作用。

在預測期內，抗菌藥物細分市場預計將呈現最高的複合年成長率。

預計在預測期內，抗菌藥物細分市場將呈現最高的複合年成長率。磺胺類藥物作為抗菌劑，在對抗細菌感染疾病中發揮至關重要的作用。磺胺類藥物因其抑菌作用而被廣泛應用，它們能夠抑制細菌葉酸的合成，從而阻止DNA和RNA的產生。這使得它們對多種致病菌有效。其抗菌應用範圍涵蓋呼吸系統、泌尿系統和皮膚感染疾病。磺胺類藥物在抗菌治療中繼續佔據著舉足輕重的地位，並為全球細菌性疾病的治療做出了重大貢獻。

市佔率最大的地區：

由於北美擁有先進的醫療基礎設施、強大的研發實力以及高感染疾病發病率，預計在整個預測期內，北美將佔據最大的市場佔有率。該地區成熟的製藥業正在推動磺胺類藥物藥物製劑的創新。此外，北美仍然是一個重要的市場，製藥領域的進步以及積極主動的感染疾病防治措施鞏固了其市場主導地位。

複合年成長率最高的地區：

亞太地區磺胺類藥物市場正經歷顯著成長，這主要得益於醫療基礎設施的改善、感染疾病流行率的上升以及人口的快速成長。該地區蓬勃發展的製藥業，以及各國政府為對抗感染疾病所做的努力，共同推動了市場需求。在亞太地區各國，磺胺類藥物在細菌感染疾病治療的應用日益廣泛，這些國家正致力於改善醫療服務的可近性。此外，持續不斷的研發活動也增強了市場的活力，使亞太地區成為磺胺類藥物市場的重要參與者。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章：執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球磺胺類藥物市場：按類型分類

  • 磺胺甲噁唑
  • 磺胺嘧啶
  • 磺胺醋醯鈉
  • 柳氮磺胺吡啶
  • 磺胺多辛
  • 其他類型

第6章 全球磺胺類藥物市場：以劑型分類

  • 藥片
  • 液體
  • 粉末
  • 其他劑型

第7章 全球磺胺類藥物市場：依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第8章 全球磺胺類藥物市場：依應用分類

  • 抗菌
  • 抗真菌劑
  • 抗瘧疾藥
  • 利尿劑
  • 抗病毒藥物
  • 其他用途

第9章 全球磺胺類藥物市場：依最終用戶分類

  • 製藥
  • 動物用藥品
  • 農業
  • 化妝品
  • 食品/飲料
  • 其他最終用戶

第10章 全球磺胺類藥物市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第11章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • Viatris Inc
  • Pfizer Inc
  • AA Pharma Inc
  • GlaxoSmithKline PLC
  • Azurity Pharmaceuticals
  • Teva Pharmaceutical Industries Limited
  • Valeo Pharma
  • Novartis Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd
  • Akorn Operating Company LLC
  • Sanofi SA
  • Roche Holding AG
  • Merck & Co.
  • Bayer AG
  • Johnson & Johnson
  • Abbott Laboratories
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
Product Code: SMRC25116

According to Stratistics MRC, the Global Sulphonamides Market is accounted for $141.53 million in 2026 and is expected to reach $245.00 million by 2034 growing at a CAGR of 7.1% during the forecast period. Sulphonamides are a class of synthetic antimicrobial drugs commonly used to treat bacterial infections. Acting as competitive inhibitors of folic acid synthesis in bacteria, they hinder essential metabolic processes, suppressing bacterial growth. Systemic sulphonamides are administered orally or parenterally for widespread infections, while topical formulations address localized issues. Their versatility extends to applications in both human and veterinary medicine.

According to NCBI, over 14 million cases of cellulitis are reported each year in the U.S., making it one of the most frequent bacterial skin infections. It is responsible for 650,000 hospital admissions per year and ambulatory care expenses of about USD 3.7 billion.

Market Dynamics:

Driver:

Increasing prevalence of infectious diseases

The mounting incidence of infectious diseases globally enhances the need for sulphonamides since these antimicrobial medicines successfully treat bacterial infections. Given the pressing need for efficient therapies against a variety of bacterial diseases, the pharmaceutical industry expects to see an increase in the use of these medications. This trend is particularly pronounced in regions with expanding populations and improving healthcare infrastructures, reinforcing sulphonamides' role in addressing the persistent challenge of infectious diseases on a broader scale.

Restraint:

Rising concerns about side effects

Concerns regarding possible side effects like rashes and allergic reactions are voiced by both patients and medical professionals, which hinders the drug's general uptake. Patients and healthcare professionals express apprehensions about potential adverse events, impacting the drug's overall adoption. The perceived risk of side effects can lead to a decline in patient compliance and reluctance among physicians to prescribe sulphonamides. This apprehension may divert preference towards alternative antibiotics or treatment options, hindering the market growth.

Opportunity:

Growing population and healthcare infrastructure

With a growing populace, the incidence of bacterial infections rises, fostering increased demand for effective treatments. Improved healthcare facilities, especially in developing regions, enhance access to sulphonamides, amplifying their usage. The strengthened healthcare infrastructure facilitates better diagnosis and treatment, promoting the adoption of sulphonamides in managing various infectious diseases. This dynamic synergy between population growth and enhanced healthcare capabilities positions sulphonamides as essential components in addressing the escalating healthcare needs of burgeoning societies.

Threat:

Limited spectrum of activity

In scenarios requiring broad-spectrum coverage, alternative antibiotics are the most favoured. Physicians, aiming for comprehensive treatments, may opt for antibiotics with a broader range of activity. The constrained scope of sulphonamides may result in their exclusion from treatment regimens, limiting their application and market share. This limitation hinders the versatility of sulphonamides, posing a challenge in situations where a more expansive antibacterial spectrum is deemed crucial for effective therapeutic interventions.

Covid-19 Impact

The covid-19 pandemic has influenced the sulphonamides market by disrupting supply chains, causing fluctuations in demand for antimicrobial agents. Healthcare priorities shifted towards managing the pandemic, impacting routine treatments. Disruptions in manufacturing and distribution channels, along with economic uncertainties, further affected the sulphonamides market. However, the essential nature of some sulphonamides in treating bacterial infections likely sustained demand, with the market adapting to ongoing challenges in the broader context of the global healthcare landscape.

The tablets segment is expected to be the largest during the forecast period

The tablets segment is estimated to have a lucrative growth. Sulphonamides tablets, a class of antimicrobial drugs, play a crucial role in treating bacterial infections. These tablets contain sulfa-based compounds that inhibit bacterial growth by interfering with folate synthesis. Commonly prescribed for urinary tract infections, respiratory tract infections, and other bacterial ailments, sulphonamide tablets offer a targeted therapeutic approach. Ongoing research aims to enhance formulations and overcome limitations, ensuring sulphonamide tablets continue to be effective and relevant in addressing a range of bacterial infections.

The antibacterial segment is expected to have the highest CAGR during the forecast period

The antibacterial segment is anticipated to witness the highest CAGR growth during the forecast period. Sulphonamides, as antibacterial agents, play a crucial role in combating bacterial infections. Widely utilized for their bacteriostatic properties, sulphonamides inhibit bacterial folate synthesis, impeding DNA and RNA production. This makes them effective against a range of bacterial pathogens. Their antibacterial application extends to respiratory, urinary, and skin infections. Sulphonamides continue to be pivotal in antibacterial therapeutics, contributing significantly to the global arsenal against bacterial diseases.

Region with largest share:

North America is projected to have the highest share over the forecast period, owing to its advanced healthcare infrastructure, robust research and development initiatives, and a high prevalence of infectious diseases. The region's well-established pharmaceutical sector fosters innovation in sulphonamide formulations. Further, North America remains a prominent market, with pharmaceutical advancements and a proactive approach toward infectious disease management fueling its continued prominence.

Region with highest CAGR:

The sulphonamides market in Asia Pacific is experiencing notable growth due to factors such as increasing healthcare infrastructure, rising prevalence of infectious diseases, and a burgeoning population. The region's expanding pharmaceutical industry, coupled with government initiatives to combat infections, propels market demand. With a focus on improving healthcare accessibility, countries in Asia Pacific are witnessing higher adoption of sulphonamides for treating bacterial infections. Additionally, ongoing research and development activities contribute to the market's dynamism, positioning Asia Pacific as a key player in the sulphonamides market.

Key players in the market

Some of the key players profiled in the Sulphonamides Market include Viatris Inc, Pfizer Inc, AA Pharma Inc, GlaxoSmithKline PLC, Azurity Pharmaceuticals, Teva Pharmaceutical Industries Limited, Valeo Pharma, Novartis Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Akorn Operating Company LLC, Sanofi S.A., Roche Holding AG, Merck & Co., Bayer AG, Johnson & Johnson, Abbott Laboratories, Bristol Myers Squibb Company, Eli Lilly and Company, AstraZeneca PLC and Boehringer Ingelheim International GmbH.

Key Developments:

In August 2022, Valeo Pharma Inc. and Novartis Pharmaceuticals Canada Inc., a subsidiary of Novartis AG, signed a supply and distribution agreement for SIMBRINZA in Canada. Brinzolamide is a carbonic anhydrase inhibitor and sulfonamide with a specific affinity for carbonic anhydrase II. This move ensured a broader reach of its products in the global market.

In July 2022, Azurity Pharmaceuticals Inc. received approval from the US FDA for ZONISADE (zonisamide oral suspension). Zonisamide is a sulfonamide antiepileptic drug.

Types Covered:

  • Sulfamethoxazole
  • Sulfadiazine
  • Sulfacetamide
  • Sulfasalazine
  • Sulfadoxine
  • Other Types

Formulations Covered:

  • Tablets
  • Liquid
  • Powder
  • Other Formulations

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Topical

Applications Covered:

  • Antibacterial
  • Antifungal
  • Antimalarial
  • Diuretic
  • Antiviral
  • Other Applications

End Users Covered:

  • Pharmaceuticals
  • Veterinary Medicine
  • Agriculture
  • Cosmetics
  • Food & Beverage
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Sulphonamides Market, By Type

  • 5.1 Introduction
  • 5.2 Sulfamethoxazole
  • 5.3 Sulfadiazine
  • 5.4 Sulfacetamide
  • 5.5 Sulfasalazine
  • 5.6 Sulfadoxine
  • 5.7 Other Types

6 Global Sulphonamides Market, By Formulation

  • 6.1 Introduction
  • 6.2 Tablets
  • 6.3 Liquid
  • 6.4 Powder
  • 6.5 Other Formulations

7 Global Sulphonamides Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral
  • 7.4 Topical

8 Global Sulphonamides Market, By Application

  • 8.1 Introduction
  • 8.2 Antibacterial
  • 8.3 Antifungal
  • 8.4 Antimalarial
  • 8.5 Diuretic
  • 8.6 Antiviral
  • 8.7 Other Applications

9 Global Sulphonamides Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceuticals
  • 9.3 Veterinary Medicine
  • 9.4 Agriculture
  • 9.5 Cosmetics
  • 9.6 Food & Beverage
  • 9.7 Other End Users

10 Global Sulphonamides Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Viatris Inc
  • 12.2 Pfizer Inc
  • 12.3 AA Pharma Inc
  • 12.4 GlaxoSmithKline PLC
  • 12.5 Azurity Pharmaceuticals
  • 12.6 Teva Pharmaceutical Industries Limited
  • 12.7 Valeo Pharma
  • 12.8 Novartis Pharmaceuticals
  • 12.9 Sun Pharmaceutical Industries Ltd
  • 12.10 Akorn Operating Company LLC
  • 12.11 Sanofi S.A.
  • 12.12 Roche Holding AG
  • 12.13 Merck & Co.
  • 12.14 Bayer AG
  • 12.15 Johnson & Johnson
  • 12.16 Abbott Laboratories
  • 12.17 Bristol Myers Squibb Company
  • 12.18 Eli Lilly and Company
  • 12.19 AstraZeneca PLC
  • 12.20 Boehringer Ingelheim International GmbH

List of Tables

  • Table 1 Global Sulphonamides Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Sulphonamides Market Outlook, By Type (2023-2034) ($MN)
  • Table 3 Global Sulphonamides Market Outlook, By Sulfamethoxazole (2023-2034) ($MN)
  • Table 4 Global Sulphonamides Market Outlook, By Sulfadiazine (2023-2034) ($MN)
  • Table 5 Global Sulphonamides Market Outlook, By Sulfacetamide (2023-2034) ($MN)
  • Table 6 Global Sulphonamides Market Outlook, By Sulfasalazine (2023-2034) ($MN)
  • Table 7 Global Sulphonamides Market Outlook, By Sulfadoxine (2023-2034) ($MN)
  • Table 8 Global Sulphonamides Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 9 Global Sulphonamides Market Outlook, By Formulation (2023-2034) ($MN)
  • Table 10 Global Sulphonamides Market Outlook, By Tablets (2023-2034) ($MN)
  • Table 11 Global Sulphonamides Market Outlook, By Liquid (2023-2034) ($MN)
  • Table 12 Global Sulphonamides Market Outlook, By Powder (2023-2034) ($MN)
  • Table 13 Global Sulphonamides Market Outlook, By Other Formulations (2023-2034) ($MN)
  • Table 14 Global Sulphonamides Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 15 Global Sulphonamides Market Outlook, By Oral (2023-2034) ($MN)
  • Table 16 Global Sulphonamides Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 17 Global Sulphonamides Market Outlook, By Topical (2023-2034) ($MN)
  • Table 18 Global Sulphonamides Market Outlook, By Application (2023-2034) ($MN)
  • Table 19 Global Sulphonamides Market Outlook, By Antibacterial (2023-2034) ($MN)
  • Table 20 Global Sulphonamides Market Outlook, By Antifungal (2023-2034) ($MN)
  • Table 21 Global Sulphonamides Market Outlook, By Antimalarial (2023-2034) ($MN)
  • Table 22 Global Sulphonamides Market Outlook, By Diuretic (2023-2034) ($MN)
  • Table 23 Global Sulphonamides Market Outlook, By Antiviral (2023-2034) ($MN)
  • Table 24 Global Sulphonamides Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 25 Global Sulphonamides Market Outlook, By End User (2023-2034) ($MN)
  • Table 26 Global Sulphonamides Market Outlook, By Pharmaceuticals (2023-2034) ($MN)
  • Table 27 Global Sulphonamides Market Outlook, By Veterinary Medicine (2023-2034) ($MN)
  • Table 28 Global Sulphonamides Market Outlook, By Agriculture (2023-2034) ($MN)
  • Table 29 Global Sulphonamides Market Outlook, By Cosmetics (2023-2034) ($MN)
  • Table 30 Global Sulphonamides Market Outlook, By Food & Beverage (2023-2034) ($MN)
  • Table 31 Global Sulphonamides Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.